Does pre-existing diabetes affect prostate cancer prognosis A systematic review

Claire Snyder, K. B. Stein, B. B. Barone, Kimberly Peairs, Hsin Chieh Yeh, R. L. Derr, Antonio C Wolff, Michael A Carducci, F. L. Brancati

Research output: Contribution to journalArticle

Abstract

To summarize the influence of pre-existing diabetes on mortality and morbidity in men with prostate cancer. We searched MEDLINE and EMBASE from inception through 1 October 2008. Search terms were related to diabetes, cancer and prognosis. Studies were included if they reported an original data analysis of prostate cancer prognosis, compared outcomes between men with and without diabetes and were in English. Titles, abstracts and articles were reviewed independently by two authors. Conflicts were settled by consensus or third review. We abstracted data on study design, analytic methods, outcomes and quality. We summarized mortality and morbidity outcomes qualitatively and conducted a preliminary meta-analysis to quantify the risk of long-term (3 months), overall mortality. In total, 11 articles were included in the review. Overall, one of four studies found increased prostate cancer mortality, one of two studies found increased nonprostate cancer mortality and one study found increased 30-day mortality. Data from four studies could be included in a preliminary meta-analysis for long-term, overall mortality and produced a pooled hazard ratio of 1.57 (95% CI: 1.12-2.20). Diabetes was also associated with receiving radiation therapy, complication rates, recurrence and treatment failure. Our analysis suggests that pre-existing diabetes affects the treatment and outcomes of men with prostate cancer.

Original languageEnglish (US)
Pages (from-to)58-64
Number of pages7
JournalProstate Cancer and Prostatic Diseases
Volume13
Issue number1
DOIs
StatePublished - Mar 2010

Fingerprint

Prostatic Neoplasms
Mortality
Meta-Analysis
Morbidity
Treatment Failure
MEDLINE
Neoplasms
Radiotherapy
Recurrence

Keywords

  • Diabetes
  • Meta-analysis
  • Prognosis
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Does pre-existing diabetes affect prostate cancer prognosis A systematic review. / Snyder, Claire; Stein, K. B.; Barone, B. B.; Peairs, Kimberly; Yeh, Hsin Chieh; Derr, R. L.; Wolff, Antonio C; Carducci, Michael A; Brancati, F. L.

In: Prostate Cancer and Prostatic Diseases, Vol. 13, No. 1, 03.2010, p. 58-64.

Research output: Contribution to journalArticle

@article{e00aefbb2c5b4ea698cf963aff800549,
title = "Does pre-existing diabetes affect prostate cancer prognosis A systematic review",
abstract = "To summarize the influence of pre-existing diabetes on mortality and morbidity in men with prostate cancer. We searched MEDLINE and EMBASE from inception through 1 October 2008. Search terms were related to diabetes, cancer and prognosis. Studies were included if they reported an original data analysis of prostate cancer prognosis, compared outcomes between men with and without diabetes and were in English. Titles, abstracts and articles were reviewed independently by two authors. Conflicts were settled by consensus or third review. We abstracted data on study design, analytic methods, outcomes and quality. We summarized mortality and morbidity outcomes qualitatively and conducted a preliminary meta-analysis to quantify the risk of long-term (3 months), overall mortality. In total, 11 articles were included in the review. Overall, one of four studies found increased prostate cancer mortality, one of two studies found increased nonprostate cancer mortality and one study found increased 30-day mortality. Data from four studies could be included in a preliminary meta-analysis for long-term, overall mortality and produced a pooled hazard ratio of 1.57 (95{\%} CI: 1.12-2.20). Diabetes was also associated with receiving radiation therapy, complication rates, recurrence and treatment failure. Our analysis suggests that pre-existing diabetes affects the treatment and outcomes of men with prostate cancer.",
keywords = "Diabetes, Meta-analysis, Prognosis, Prostate cancer",
author = "Claire Snyder and Stein, {K. B.} and Barone, {B. B.} and Kimberly Peairs and Yeh, {Hsin Chieh} and Derr, {R. L.} and Wolff, {Antonio C} and Carducci, {Michael A} and Brancati, {F. L.}",
year = "2010",
month = "3",
doi = "10.1038/pcan.2009.39",
language = "English (US)",
volume = "13",
pages = "58--64",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Does pre-existing diabetes affect prostate cancer prognosis A systematic review

AU - Snyder, Claire

AU - Stein, K. B.

AU - Barone, B. B.

AU - Peairs, Kimberly

AU - Yeh, Hsin Chieh

AU - Derr, R. L.

AU - Wolff, Antonio C

AU - Carducci, Michael A

AU - Brancati, F. L.

PY - 2010/3

Y1 - 2010/3

N2 - To summarize the influence of pre-existing diabetes on mortality and morbidity in men with prostate cancer. We searched MEDLINE and EMBASE from inception through 1 October 2008. Search terms were related to diabetes, cancer and prognosis. Studies were included if they reported an original data analysis of prostate cancer prognosis, compared outcomes between men with and without diabetes and were in English. Titles, abstracts and articles were reviewed independently by two authors. Conflicts were settled by consensus or third review. We abstracted data on study design, analytic methods, outcomes and quality. We summarized mortality and morbidity outcomes qualitatively and conducted a preliminary meta-analysis to quantify the risk of long-term (3 months), overall mortality. In total, 11 articles were included in the review. Overall, one of four studies found increased prostate cancer mortality, one of two studies found increased nonprostate cancer mortality and one study found increased 30-day mortality. Data from four studies could be included in a preliminary meta-analysis for long-term, overall mortality and produced a pooled hazard ratio of 1.57 (95% CI: 1.12-2.20). Diabetes was also associated with receiving radiation therapy, complication rates, recurrence and treatment failure. Our analysis suggests that pre-existing diabetes affects the treatment and outcomes of men with prostate cancer.

AB - To summarize the influence of pre-existing diabetes on mortality and morbidity in men with prostate cancer. We searched MEDLINE and EMBASE from inception through 1 October 2008. Search terms were related to diabetes, cancer and prognosis. Studies were included if they reported an original data analysis of prostate cancer prognosis, compared outcomes between men with and without diabetes and were in English. Titles, abstracts and articles were reviewed independently by two authors. Conflicts were settled by consensus or third review. We abstracted data on study design, analytic methods, outcomes and quality. We summarized mortality and morbidity outcomes qualitatively and conducted a preliminary meta-analysis to quantify the risk of long-term (3 months), overall mortality. In total, 11 articles were included in the review. Overall, one of four studies found increased prostate cancer mortality, one of two studies found increased nonprostate cancer mortality and one study found increased 30-day mortality. Data from four studies could be included in a preliminary meta-analysis for long-term, overall mortality and produced a pooled hazard ratio of 1.57 (95% CI: 1.12-2.20). Diabetes was also associated with receiving radiation therapy, complication rates, recurrence and treatment failure. Our analysis suggests that pre-existing diabetes affects the treatment and outcomes of men with prostate cancer.

KW - Diabetes

KW - Meta-analysis

KW - Prognosis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=76949099436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76949099436&partnerID=8YFLogxK

U2 - 10.1038/pcan.2009.39

DO - 10.1038/pcan.2009.39

M3 - Article

VL - 13

SP - 58

EP - 64

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 1

ER -